what compound is cagrilintide | C194H312N54O59S2 | CID 171397054 Cagrilintide (10mg) - LGI peptides

Apply these five checks to the popular claim retatrutide is far better than cagrilintide and it quickly reduces to: a 48-week top-dose monotherapy number for one, next to a 26-week monotherapy number for the other whose real strength is a combination with no head-to-head trial anywhere in the chain

Comparing the raw numbers as if they were a head-to-head duel manufactures a certainty the evidence does not support

The defensible, peer-reviewed statement is: standalone cagrilintide produced about 10.8% at 26 weeks at 4.5 mg in Phase 2

[1] The more advanced regulatory activity belongs to the combination product CagriSema (cagrilintide plus semaglutide), which reached Phase 3 and for which a New Drug Application was reported to have been filed with the FDA in late 2025